Bystolic

Bystolic is a brand name of nebivolol, approved by the FDA in the following formulation(s):

BYSTOLIC (nebivolol hydrochloride - tablet; oral)

• 
  Manufacturer: FOREST LABS
  
  Approval date: December 17, 2007
  
  Strength(s): EQ 10MG BASE, EQ 2.5MG BASE, EQ 5MG BASE
  


• 
  Manufacturer: FOREST LABS
  
  Approval date: October 8, 2008
  
  Strength(s): EQ 20MG BASE ^[RLD]

Has a generic version of Bystolic been approved?

No. There is currently no therapeutically equivalent version of Bystolic available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bystolic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Compositions containing micronized nebivolol
  Patent 5,759,580
  Issued: June 2, 1998
  Inventor(s): Jans; Eugeen Marie Jozef & Smans; Guido Franciscus & Gilis; Paul Marie Victor
  Assignee(s): Janssen Pharmaceutica, N.V.
  The present invention relates to pharmaceutical compositions containing as active ingredient micronized nebivolol of formula (I) and ways of preparing said compositions. ##STR1##
  
  Patent expiration dates:
  
  
  • June 2, 2015
    
    ✓ 
    Drug product
  
  



• 
  Method of lowering the blood pressure
  Patent 6,545,040
  Issued: April 8, 2003
  Inventor(s): Raymond Mathieu; Xhonneux & Guy Rosalia Eugène; Van Lommen
  Assignee(s): Janssen Pharmaceutica N.V.
  A method of potentiating the effects of blood pressure reducing agents in warm-blooded animals, said method comprising administering to said warm-blooded animals of an effective amount of a blood pressure reducing agent and a 2,2′-iminobisethanol derivative.
  
  Patent expiration dates:
  
  
  • December 17, 2021
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 17, 2012 - NEW CHEMICAL ENTITY
  
  

See also...

• Bystolic Consumer Information (Drugs.com)
• Bystolic Consumer Information (Wolters Kluwer)
• Bystolic Consumer Information (Cerner Multum)
• Bystolic Advanced Consumer Information (Micromedex)
• Bystolic AHFS DI Monographs (ASHP)
• Nebivolol Consumer Information (Wolters Kluwer)
• Nebivolol Consumer Information (Cerner Multum)
• Nebivolol Advanced Consumer Information (Micromedex)
• Nebivolol Hydrochloride AHFS DI Monographs (ASHP)